In yesterday’s Wall Street session, cbdMD Inc. (AMEX:YCBD) shares traded at $0.30, down -0.07% from the previous session.
As of this writing, 1 analysts cover cbdMD Inc. (AMEX:YCBD). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $5.00 and a low of $2.40, we find $3.70. Given the previous closing price of $0.30, this indicates a potential upside of 1133.33 percent. YCBD stock price is now 9.64% away from the 50-day moving average and -29.71% away from the 200-day moving average. The market capitalization of the company currently stands at $18.81M.
There are 1 analysts who have given it a hold rating, whereas 0 have given it a buy rating. Brokers who have rated the stock have averaged $3.70 as their price target over the next twelve months.
A total of 29.23% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in YCBD stock. A new stake in cbdMD Inc. shares was purchased by SENTINUS, LLC during the first quarter worth $256,000. EXODUSPOINT CAPITAL MANAGEMENT, LP invested $43,000 in shares of YCBD during the first quarter. In the first quarter, TOWER RESEARCH CAPITAL LLC (TRC) acquired a new stake in cbdMD Inc. valued at approximately $4,000. In total, there are 60 active investors with 13.50% ownership of the company’s stock.
Monday morning saw cbdMD Inc. (AMEX: YCBD) opened at $0.3000. During the past 12 months, cbdMD Inc. has had a low of $0.20 and a high of $1.30. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 3.00, and a quick ratio of 2.20. The fifty day moving average price for YCBD is $0.2737 and a two-hundred day moving average price translates $0.4270 for the stock.
The latest earnings results from cbdMD Inc. (AMEX: YCBD) was released for Jun, 2022. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at -$0.03, beating analysts’ expectations of -$0.04 by 0.01. This compares to -$0.04 EPS in the same period last year. The company reported revenue of $7.86 million for the quarter, compared to $9.79 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -19.74 percent. For the current quarter, analysts expect YCBD to generate $10M in revenue.
cbdMD Inc.(YCBD) Company Profile
cbdMD, Inc. produces and distributes various cannabidiol (CBD) products. The company owns and operates consumer hemp-based CBD brands, such as cbdMD, Paw CBD, and cbdMD Botanicals. Its cbdMD brand products include CDB tinctures, gummies, topicals, capsules, bath bombs, bath salts, and sleep aids. It also offers veterinarian-formulated products, including tinctures, chews, and topicals under the Paw CBD brand name. The company distributes its products through its e-commerce Website, third-party e-commerce sites, wholesalers, and various brick and mortar retailers in the United States. It has a research partnership with the University of Mississippi to identify novel cannabinoids. The company was formerly known as Level Brands, Inc. and changed its name to cbdMD, Inc. in May 2019. cbdMD, Inc. was incorporated in 2015 and is headquartered in Charlotte, North Carolina.